Benefit assessment in Germany: implications for price discounts.

ABSTRACT:

Background

The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional benefit by the GBA, the manufacturer is entitled to negotiate the reimbursement price with the GKV-SV (National Association of Statutory Health Insurance Funds). The reimbursement price is defined as a discount on the drug price at launch. As the price or discount negotiations between the manufacturers and the GKV-SV takes place behind closed doors, the factors influencing the results of the negotiation are not known.

Objectives

The aim of this evaluation is to identify factors influen

SUBMITTER: Theidel U 

PROVIDER: S-EPMC4970987 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature